<DOC>
	<DOCNO>NCT01646125</DOCNO>
	<brief_summary>The purpose study determine AUY922 superior efficacy compare chemotherapy agent docetaxel pemetrexed patient whose tumor EGFR mutation . The primary purpose study compare efficacy AUY922 , administer i.v . once-weekly schedule 70 mg/m2 , versus docetaxel pemetrexed adult patient advance NSCLC , whose tumor harbor EGFR activate mutation , develop resistance EGFR TKI .</brief_summary>
	<brief_title>An Open-label , Randomized Phase II Study Evaluate Efficacy AUY922 v Pemetrexed Docetaxel NSCLC Patients With EGFR Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients histologically cytologically document , locally advanced ( stage IIIB amenable combined modality treatment ) recurrent metastatic ( Stage IV ) nonsmall cell lung cancer . 2 . Patients must EGFR gene mutation tumor . This source document one following : • Provide pathology report indicate patient 's tumor EGFR activate mutation past . Or : • Perform testing ( local central ) archival tumor fresh baseline biopsy tumor tissue show presence EGFR activate mutation . 3 . Patients must document clinical benefit ( CR , PR , patient SD 6 month great ) prior EGFR TKI ( e.g . erlotinib gefitinib ) follow document progression accord RECIST . 4 . Patients must receive prior platinum contain treatment . 5. WHO performance status 01 1 . Patients receive two prior line antineoplastic therapy advance disease . Chemotherapy administer neoadjuvant adjuvant treatment six month prior study enrollment consider prior line therapy purpose study . 2 . Evidence spinal cord compression current evidence CNS metastasis . Screening CT/MRI brain mandatory . Note : Patients treat CNS metastasis radiation gamma knife surgery , stable least 2 month discontinue high dose corticosteroid eligible protocol participation 3 . Prior treatment HSP90 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-small cell lung carcinoma ( NSCLC )</keyword>
	<keyword>treatment lung cancer first metastasis</keyword>
	<keyword>lung cancer</keyword>
	<keyword>lung adenocarcinoma</keyword>
	<keyword>Squamous cell lung carcinoma</keyword>
	<keyword>Large-cell lung carcinoma</keyword>
	<keyword>Non small cell lung carcinoma</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Large cell lung carcinoma</keyword>
	<keyword>Large cell lung cancer</keyword>
	<keyword>HSP90</keyword>
	<keyword>AUY922</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>EGFR TKI</keyword>
	<keyword>EGFR mutation</keyword>
</DOC>